CD274 and neoplasm: One can hypothesize that different responses to checkpoint inhibitor therapy could be a consequence of heterogeneous intra- and inter-tumor expression of different kinds of checkpoints, though data on the expression status of ILTs and CTLA-4 and PD-L1 in cancers are rather limited.